ArticleScientific reports2025
Application of chemical similarity and bioisosteres to find allosteric inhibitors of type 2 lipid kinase γ.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phosphatidylinositol phosphate kinases (PIPKs) exist in three isoforms: I, II, and III. Some of these enzymes are promising drug targets for cancer, metabolic disorders, and neurodegenerative diseases. Type II PIPKs are notable for their dual roles, to perform phosphorylation reactions acting as lipid kinases and to carry out catalytic-independent functions. The dysregulation of Type II PIPKs is linked to several diseases, including psychiatric disorders, cancer, and infections. There is still a need to explore for strong inhibitors of these kinases. This study used a similarity search method to find analogs of the known PI5P4K2C inhibitor, DVF (5-methyl-2-(2-propan-2-ylphenyl)-N-(pyridin-2-ylmethyl)pyrrolo[3,2-d]pyrimidin-4-amine). It utilized open-access platforms like SwissSimilarity, SwissBioisosteres, and the STITCH database for the initial screening of molecules. Drug-likeness assessment of the selected molecules was followed by molecular docking and molecular dynamics simulations to evaluate their binding affinity and stability. Post-simulation analysis revealed four promising hit compounds, each containing a pyrrole-pyrimidine core, which exhibited superior binding free energies and interactions at the allosteric site compared to DVF. These findings highlight potential candidates for further development as PI5P4K2C inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.